Literature DB >> 25376524

Germline PTEN, SDHB-D, and KLLN alterations in endometrial cancer patients with Cowden and Cowden-like syndromes: an international, multicenter, prospective study.

Haider Mahdi1, Jessica L Mester, Emily A Nizialek, Joanne Ngeow, Chad Michener, Charis Eng.   

Abstract

BACKGROUND: Endometrial cancer has been recognized only recently as a major component of Cowden syndrome (CS). Germline alterations in phosphatase and tensin homolog (PTEN; PTEN_mut+), succinate dehydrogenase B/C/D (SDHB-D; SDHx_var+), and killin (KLLN_Me+) cause CS and Cowden syndrome-like (CSL) phenotypes. This study was aimed at identifying the prevalence and clinicopathologic predictors of germline PTEN_mut+, SDHx_var+, and KLLN_Me+ in CS/CSL patients presenting with endometrial cancer.
METHODS: PTEN and SDHB-D mutation and KLLN promoter methylation analyses were performed for 371 prospectively enrolled patients (2005-2011). PTEN protein was analyzed from patient-derived lymphoblast lines. The PTEN Cleveland Clinic (CC) score is a weighted, regression-based risk calculator giving the a priori risk for PTEN_mut+. Demographic and clinicopathologic features were correlated with the specific gene.
RESULTS: Germline PTEN_mut+, SDHx_var+, and KLLN_Me+ were found in 7%, 9.8%, and 10.5% of informative samples, respectively. Predictors of PTEN_mut+ included an age ≤ 50 years (odds ratio [OR] for an age < 30 years, 6.1 [P = .015]; OR for an age of 30-50 years, 4.4 [P = .001]), macrocephaly (OR, 14.4; P < .001), a higher CC score (OR for a 1-U increment, 1.35; P < .001), a PTEN protein level within the lowest quartile (OR, 5.1; P = .039), and coexisting renal cancer (OR, 5.7; P = .002). KLLN_Me+ patients were on average 8 years younger than KLLN_Me- patients (44 vs 52 years, P = .018). Predictors of KLLN_Me+ were a younger age and a higher CC score. On the other hand, no clinical predictors of SDH_var+ were found.
CONCLUSIONS: Clinical predictors of PTEN and KLLN alterations, but not SDHx_var+, were identified. These predictors should alert the treating physician to potential heritable risk and the need for referral to genetic professionals. High-risk cancer surveillance and prophylactic surgery of the uterus may be considered for KLLN_Me+ patients similarly to PTEN_mut+ patients.
© 2014 American Cancer Society.

Entities:  

Keywords:  Cowden syndrome; Cowden-like syndrome; endometrial cancer; killin (KLLN); phosphatase and tensin homolog (PTEN); succinate dehydrogenase B/D (SDHB-D)

Mesh:

Substances:

Year:  2014        PMID: 25376524      PMCID: PMC4339629          DOI: 10.1002/cncr.29106

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  Tissue specific DNA methylation of CpG islands in normal human adult somatic tissues distinguishes neural from non-neural tissues.

Authors:  Srimoyee Ghosh; Allan J Yates; Michael C Frühwald; Jeffrey C Miecznikowski; Christoph Plass; Dominic Smiraglia
Journal:  Epigenetics       Date:  2010-08-16       Impact factor: 4.528

2.  Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.

Authors:  Kristi L Bennett; Jessica Mester; Charis Eng
Journal:  JAMA       Date:  2010-12-22       Impact factor: 56.272

3.  Diagnostic guidelines for high-resolution melting curve (HRM) analysis: an interlaboratory validation of BRCA1 mutation scanning using the 96-well LightScanner.

Authors:  Nienke van der Stoep; Chantal D M van Paridon; Tom Janssens; Petra Krenkova; Alexandra Stambergova; Milan Macek; Gert Matthijs; Egbert Bakker
Journal:  Hum Mutat       Date:  2009-06       Impact factor: 4.878

4.  A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands.

Authors:  Min-Han Tan; Jessica Mester; Charissa Peterson; Yiran Yang; Jin-Lian Chen; Lisa A Rybicki; Kresimira Milas; Holly Pederson; Berna Remzi; Mohammed S Orloff; Charis Eng
Journal:  Am J Hum Genet       Date:  2010-12-30       Impact factor: 11.025

5.  Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations.

Authors:  M R Nelen; H Kremer; I B Konings; F Schoute; A J van Essen; R Koch; C G Woods; J P Fryns; B Hamel; L H Hoefsloot; E A Peeters; G W Padberg
Journal:  Eur J Hum Genet       Date:  1999-04       Impact factor: 4.246

6.  Large germline deletions of mitochondrial complex II subunits SDHB and SDHD in hereditary paraganglioma.

Authors:  Sarah R McWhinney; Robert T Pilarski; Shawnia R Forrester; Michael C Schneider; M Marta Sarquis; Eduardo P Dias; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

7.  Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes.

Authors:  Ying Ni; Kevin M Zbuk; Tammy Sadler; Attila Patocs; Glenn Lobo; Emily Edelman; Petra Platzer; Mohammed S Orloff; Kristin A Waite; Charis Eng
Journal:  Am J Hum Genet       Date:  2008-08       Impact factor: 11.025

8.  Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly.

Authors:  Joseph D Buxbaum; Guiqing Cai; Pauline Chaste; Gudrun Nygren; Juliet Goldsmith; Jennifer Reichert; Henrik Anckarsäter; Maria Rastam; Christopher J Smith; Jeremy M Silverman; Eric Hollander; Marion Leboyer; Christopher Gillberg; Alain Verloes; Catalina Betancur
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-06-05       Impact factor: 3.568

9.  Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation.

Authors:  Rosemary E Teresi; Kevin M Zbuk; Marcus G Pezzolesi; Kristin A Waite; Charis Eng
Journal:  Am J Hum Genet       Date:  2007-08-15       Impact factor: 11.025

10.  Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements.

Authors:  Marcel W Coolen; Aaron L Statham; Margaret Gardiner-Garden; Susan J Clark
Journal:  Nucleic Acids Res       Date:  2007-09-13       Impact factor: 16.971

View more
  13 in total

Review 1.  Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing.

Authors:  Amanda B Spurdle; Michael A Bowman; Jannah Shamsani; Judy Kirk
Journal:  Mod Pathol       Date:  2017-04-28       Impact factor: 7.842

2.  Diagnosis and management of an endometrial cancer patient with Cowden syndrome.

Authors:  Beryl L Manning-Geist; Sonia Gatius; Ying Liu; Mabel Gil; Arnaud Da Cruz Paula; Noemi Tuset; Nadeem R Abu-Rustum; Carol Aghajanian; Britta Weigelt; Xavier Matias-Guiu
Journal:  Gynecol Oncol       Date:  2021-08-23       Impact factor: 5.304

Review 3.  Central precocious puberty: Recent advances in understanding the aetiology and in the clinical approach.

Authors:  Luigi Maione; Claire Bouvattier; Ursula B Kaiser
Journal:  Clin Endocrinol (Oxf)       Date:  2021-04-20       Impact factor: 3.523

Review 4.  Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?

Authors:  Adele Wong; Joanne Ngeow
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

5.  Exome sequencing reveals germline gain-of-function EGFR mutation in an adult with Lhermitte-Duclos disease.

Authors:  Samantha Colby; Lamis Yehia; Farshad Niazi; JinLian Chen; Ying Ni; Jessica L Mester; Charis Eng
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-11

Review 6.  Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.

Authors:  Seiichi Mori; Osamu Gotoh; Kazuma Kiyotani; Siew Kee Low
Journal:  J Hum Genet       Date:  2021-06-07       Impact factor: 3.172

7.  XTEN as Biological Alternative to PEGylation Allows Complete Expression of a Protease-Activatable Killin-Based Cytostatic.

Authors:  Akvile Haeckel; Franziska Appler; Angela Ariza de Schellenberger; Eyk Schellenberger
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

8.  Hamartoma-like lesions in the mouse retina: an animal model of Pten hamartoma tumour syndrome.

Authors:  Nobuhiko Tachibana; Yacine Touahri; Rajiv Dixit; Luke Ajay David; Lata Adnani; Robert Cantrup; Tooka Aavani; Rachel O Wong; Cairine Logan; Kyle C Kurek; Carol Schuurmans
Journal:  Dis Model Mech       Date:  2018-05-21       Impact factor: 5.758

9.  Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer.

Authors:  Günter Emons; Eric Steiner; Dirk Vordermark; Christoph Uleer; Nina Bock; Kerstin Paradies; Olaf Ortmann; Stefan Aretz; Peter Mallmann; Christian Kurzeder; Volker Hagen; Birgitt van Oorschot; Stefan Höcht; Petra Feyer; Gerlinde Egerer; Michael Friedrich; Wolfgang Cremer; Franz-Josef Prott; Lars-Christian Horn; Heinrich Prömpeler; Jan Langrehr; Steffen Leinung; Matthias W Beckmann; Rainer Kimmig; Anne Letsch; Michael Reinhardt; Bernd Alt-Epping; Ludwig Kiesel; Jan Menke; Marion Gebhardt; Verena Steinke-Lange; Nils Rahner; Werner Lichtenegger; Alain Zeimet; Volker Hanf; Joachim Weis; Michael Mueller; Ulla Henscher; Rita K Schmutzler; Alfons Meindl; Felix Hilpert; Joan Elisabeth Panke; Vratislav Strnad; Christiane Niehues; Timm Dauelsberg; Peter Niehoff; Doris Mayr; Dieter Grab; Michael Kreißl; Ralf Witteler; Annemarie Schorsch; Alexander Mustea; Edgar Petru; Jutta Hübner; Anne Derke Rose; Edward Wight; Reina Tholen; Gerd J Bauerschmitz; Markus Fleisch; Ingolf Juhasz-Boess; Lax Sigurd; Ingo Runnebaum; Clemens Tempfer; Monika J Nothacker; Susanne Blödt; Markus Follmann; Thomas Langer; Heike Raatz; Simone Wesselmann; Saskia Erdogan
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-10-19       Impact factor: 2.915

10.  SuMO-Fil: Supervised multi-omic filtering prior to performing network analysis.

Authors:  Lorin M Towle-Miller; Jeffrey C Miecznikowski; Fan Zhang; David L Tritchler
Journal:  PLoS One       Date:  2021-08-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.